Ireland - English - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - ramipril - tablet - 10 milligram(s) - ace inhibitors, plain; ramipril

Ireland - English - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - ramipril - tablet - 1.25 milligram(s) - ace inhibitors, plain; ramipril

Ireland - English - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - ramipril - tablet - 5 milligram(s) - ace inhibitors, plain; ramipril

Malta - English - Medicines Authority

amneal pharma europe limited - ramipril - tablet - ramipril 5 mg - agents acting on the renin-angiotensin system

Malta - English - Medicines Authority

amneal pharma europe limited - ramipril - tablet - ramipril 10 mg - agents acting on the renin-angiotensin system

Malta - English - Medicines Authority

amneal pharma europe limited - ramipril - tablet - ramipril 1.25 mg - agents acting on the renin-angiotensin system

Malta - English - Medicines Authority

amneal pharma europe limited - ramipril - tablet - ramipril 2.5 mg - agents acting on the renin-angiotensin system

Malta - English - Medicines Authority

aurobindo pharma (malta) limited vault 14, level 2, valletta waterfront, floriana frn 1913, malta - ramipril - tablet - ramipril 1.25 mg - agents acting on the renin-angiotensin system

Malta - English - Medicines Authority

aurobindo pharma (malta) limited vault 14, level 2, valletta waterfront, floriana frn 1913, malta - ramipril - tablet - ramipril 2.5 mg - agents acting on the renin-angiotensin system

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - ramipril, quantity: 5 mg - capsule - excipient ingredients: hydrophobic colloidal silica anhydrous; pregelatinised maize starch; titanium dioxide; purified water; gelatin; sodium lauryl sulfate; brilliant scarlet 4r; patent blue v - - treatment of hypertension. data are currently not available to support the use of ramipril in renovascular hypertension. - post mi heart failure, - prevention of progressive renal failure in patients with persistent proteinuria in excess of 1 g/day. - for reducing the risk of myocardial infarction, stroke, cardiovascular death or the need for revascularisation procedures in patients 55 years of age or more who have clinical evidence of coronary artery disease, stroke, or peripheral vascular disease. - for reducing the risk of myocardial infarction, stroke, cardiovascular death or revascularisation procedures in diabetic patients 55 years or more with one or more of the following risk factors: systolic blood pressure >160mmhg or diastolic blood pressure >90mmhg (or on antihypertensive treatment); total cholesterol >5.2mmol/l; hdl cholesterol <0.9mmol/l; current smoker; known microalbuminuria; any evidence of previous vascular disease.